A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
Authors
Plummer, R.Dean, Emma J
Arkenau, H. T.
Redfern, C.
Spira, A. I.
Melear, J. M.
Chung, K. Y.
Ferrer-Playan, J.
Goddemeier, T.
Locatelli, G.
Dong, J.
Fleuranceau-Morel, P.
Diaz-Padilla, I.
Shapiro, G. I.
Affiliation
Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.Issue Date
2021
Metadata
Show full item recordCitation
Plummer R, Dean E, Arkenau H-T, Redfern C, Spira AI, Melear JM, et al. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer Vol. 163, Lung Cancer. Elsevier BV; 2022. p. 19–26.Journal
Lung CancerDOI
10.1016/j.lungcan.2021.11.011PubMed ID
34894455Type
Articleae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2021.11.011
Scopus Count
Collections
Related articles
- Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
- Authors: Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R
- Issue date: 2021 Aug
- Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
- Authors: Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA
- Issue date: 2021 Aug
- Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
- Authors: Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN Jr
- Issue date: 2021 Oct 1
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
- Authors: Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA
- Issue date: 2020 Jul
- Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
- Authors: Terranova N, Jansen M, Falk M, Hendriks BS
- Issue date: 2021 Feb